Shamaila Munir

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Inflammation induced PD-L1-specific T cells.

Inflammation induced PD-L1-specific T cells.

Journal: Cell stress

Published: October 28, 2019

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

Journal: Cancer research

Published: October 13, 2014

Functional characterization of Foxp3-specific spontaneous immune responses.

Functional characterization of Foxp3-specific spontaneous immune responses.

Journal: Leukemia

Published: May 17, 2013

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

Journal: Leukemia

Published: May 11, 2013

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Journal: Cancer research

Published: January 19, 2013

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells.

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells.

Journal: Oncoimmunology

Published: January 17, 2013

Characterization of T-cell responses against IκBα in cancer patients.

Characterization of T-cell responses against IκBα in cancer patients.

Journal: Oncoimmunology

Published: December 18, 2012

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

Journal: Cancer immunology, immunotherapy : CII

Published: December 23, 2011

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.

Journal: PloS one

Published: October 04, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026